ArticleCancer innovation2023

Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study.

Ying Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.